{"id":11238,"date":"2010-06-30T18:00:00","date_gmt":"2010-06-30T18:00:00","guid":{"rendered":""},"modified":"2016-03-24T16:35:59","modified_gmt":"2016-03-24T16:35:59","slug":"metforminas-naujos-galimybes-ir-perspektyvos","status":"publish","type":"post","link":"https:\/\/www.pasveik.lt\/lt\/naujausi-medicinos-straipsniai\/metforminas-naujos-galimybes-ir-perspektyvos\/11238\/","title":{"rendered":"Metforminas: naujos galimyb\u0117s ir perspektyvos"},"content":{"rendered":"<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 11.0pt;\">\u0160irdies ir kraujagysli\u0173 ligos daugumoje pasaulio \u0161ali\u0173 teb\u0117ra svarbiausia gyventoj\u0173 sergamumo ir mirtingumo prie\u017eastis. J\u0173 atsiradim\u0105 ir progresavim\u0105 skatina <a href=\"https:\/\/pasveik.lt\/ligos-ir-sindromai\/arterine-hipertenzija\/4333\">arterin\u0117 hipertenzija<\/a>, sutrikusi lipid\u0173 pusiausvyra, u\u017edegimo ir kitokie, dar ne visi\u0161kai identifikuoti kraujagysles pa\u017eeid\u017eiantys veiksniai. Pastaraisiais metais atlikti moksliniai tyrimai rodo, kad \u0161irdies ir kraujagysli\u0173 lig\u0173 (\u0160KL) rizikos strukt\u016broje reik\u0161mingas vaidmuo tenka \u0161iems veiksniams: <a href=\"https:\/\/pasveik.lt\/ligos-ir-sindromai\/cukrinis-diabetas\/4406\">cukriniam diabetui <\/a>(CD), atsparumui insulinui ir kitiems metabolizmo sutrikimams, taip pat antsvoriui ir nutukimui. \u012esid\u0117m\u0117tina, kad visos \u0161ios patologin\u0117s b\u016bkl\u0117s, ne tik skatina formuotis \u0161irdies ir kraujagysli\u0173 pa\u017eeidimus, bet ir yra tarpusavyje susijusios patofiziologiniais ry\u0161iais.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 11.0pt;\">\u00a0<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><b><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 13.0pt;\">Gr\u0117smingi nevaldomos rizikos padariniai<\/span><\/b><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">\u00a0<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Apie 80 proc. sergan\u010di\u0173j\u0173 2 tipo CD turi padid\u0117jus\u012f arterin\u012f kraujo spaudim\u0105, pana\u0161iai daliai nutukusi\u0173 asmen\u0173 nustatoma hipertenzija. Moksliniai tyrimai parod\u0117, kad <a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/nutukimas\/4355\">nutukimas<\/a> <i>perse <\/i>ne tik skatina did\u0117ti arterin\u012f kraujosp\u016bd\u012f, bet ma\u017eina audini\u0173 l\u0105steli\u0173 jautrum\u0105 insulinui (didina atsparum\u0105) ir yra vienas svarbiausi\u0173 2 tipo CD rizikos veiksni\u0173.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Hipertenzija, dislipidemija, atsparumas insulinui arba 2 tipo CD kartu su hipersimpatikotonija sudaro vadinam\u0105j\u012f metabolin\u012f sindrom\u0105, kurio patogenezinis ry\u0161is su \u0160KL ir j\u0173 komplikacijomis gerai \u012frodytas. Kita vertus, tinkama vieno i\u0161 rizikos veiksni\u0173 kontrol\u0117 gali susilpninti kit\u0173 veiksni\u0173 rai\u0161k\u0105.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Nustatyta, kad efektyvus arterin\u0117s hipertenzijos gydymas gali apsaugoti nuo 2 tipo CD atsiradimo esant metaboliniam sindromui, ypa\u010d jei skiriama palankiu apsauginiu poveikiu pasi\u017eymin\u010di\u0173 antihipertenzini\u0173 vaist\u0173.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Moksliniai tyrimai ir klinikin\u0117 praktika \u012frod\u0117, kad pavieni\u0173 rizikos veiksni\u0173 (pavyzd\u017eiui, vien r\u016bkymo, dislipidemijos ar hipertenzijos) korekcija nepaj\u0117gi patikimai suma\u017einti sergamumo \u0160KL, ne\u012fgalumo ir mirtingumo. Daug efektyviau pa\u0161alinti ar kontroliuoti vis\u0105 kompleks\u0105 rizikos veiksni\u0173, nors tai padaryti prakti\u0161kai gerokai sunkiau. Tam prireikia ne tik pakeisti gyvensen\u0105, elgsen\u0105, bet ir vartoti tam tikr\u0173 vaist\u0173.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><b><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 13.0pt;\">\u00a0<\/span><\/b><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><b><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 13.0pt;\">Profilaktika vaistais<\/span><\/b><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">\u00a0<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Apsaugant nuo \u0161irdies ir kraujagysli\u0173 sistemos pa\u017eeidim\u0173 svarbus vaidmuo tenka farmakoterapijai. Pasirinktiniai vaistai yra tie, kurie pasi\u017eymi naudingu pleotropiniu poveikiu, neleid\u017eian\u010diu formuotis pa\u017eeidimams ar stabdan\u010diu j\u0173 progresavim\u0105.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Toki\u0173 vaist\u0173 kategorijai priskiriami nauj\u0173j\u0173 klasi\u0173 antihipertenziniai vaistai (ypa\u010d veikiantys renino angiotenzino sistem\u0105) ir preparatai, normalizuojantys sutrikus\u012f gliukoz\u0117s ir lipid\u0173 metabolizm\u0105. Antihipertenzini\u0173 vaist\u0173 pasirinkimas i\u0161ties yra labai didelis, o angliavandeni\u0173 ir lipid\u0173 metabolizmui koreguoti tinkam\u0173 efektyvi\u0173 ir patogi\u0173 vartoti preparat\u0173 (geriam\u0173j\u0173, saugi\u0173) labai stokojama. Unikalus ir universalus \u0161iuo po\u017ei\u016briu \u2013 tiktai metforminas. Pastar\u0173j\u0173 met\u0173 tyrimai \u012frod\u0117 metformin\u0105 turint ne tik labai palank\u0173 metabolin\u012f poveik\u012f gliukoz\u0117s ir lipid\u0173 apykaitai, bet ir ry\u0161ki\u0173 \u0161ird\u012f, inkstus apsaugan\u010di\u0173 savybi\u0173. Tai paskatino ekspertus \u012ftraukti metformin\u0105 \u012f naujausias \u0160iaur\u0117s Amerikos CD gydymo gydymo ir profilaktikos gaires kaip vaist\u0105, pirmiausiai pasirenkam\u0105 visais 2 tipo CD raidos etapais \u2013 nuo lengvo ir vidutinio sunkumo iki sunkaus (kartu su insulinais ir kt.).<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Naujausi klinikiniai tyrimai rodo, kad metforminas yra vienas geriausi\u0173 vaist\u0173 gydant nutukusi\u0173 asmen\u0173 metabolinius sutrikimus, policistini\u0173 kiau\u0161id\u017ei\u0173 sindrom\u0105, u\u017ekertant keli\u0105 CD ir daugeliui kit\u0173 pavojing\u0173 patologini\u0173 b\u016bkli\u0173.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><b><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 13.0pt;\">\u00a0<\/span><\/b><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><b><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 13.0pt;\"><a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/nutukimas\/4355\">Nutukimas<\/a> \u2013 sunki\u0173 lig\u0173 prana\u0161as<\/span><\/b><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">\u00a0<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\"><a href=\"https:\/\/pasveik.lt\/ligos-ir-sindromai\/nutukimas\/4355\">Nutukim\u0105<\/a> neperdedant galima pavadinti nauj\u0173j\u0173 laik\u0173 pandemija, kurios pasekm\u0117s (\u017emoni\u0173 mirtys ir kiti skaud\u016bs praradimai) n\u0117 kiek ne lengvesn\u0117s nei viduram\u017eiais siautusi\u0173 gr\u0117sming\u0173 maro ar raup\u0173 infekcij\u0173. Vilniaus universiteto ligonin\u0117s Santari\u0161ki\u0173 klinik\u0173 gydytoja endokrinolog\u0117 \u017dydr\u016bn\u0117 Visockien\u0117 sako, kad pasaulis nenumaldomai tunka, o tai daro neatitaisom\u0105 \u017eal\u0105 visuomen\u0117s sveikatai, valstybi\u0173 ekonomikai, \u017emoni\u0173 gerovei. Nutukusi \u201etradici\u0161kai\u201c jau ne tik Amerika, bet ir daugelis kit\u0173 stiprios ekonomikos \u0161ali\u0173.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Pana\u0161i\u0173 tendencij\u0173 pastebima ir Centrin\u0117s bei Ryt\u0173 Europos regione, netgi kai kuriose tre\u010diojo pasaulio \u0161alyse. K\u016bno svoriui \u012fvertinti taikomas k\u016bno mas\u0117s indeksas (KMI), normalus jo rodiklis yra 18\u201324,9. Naujausi epidemiologiniai tyrimai rodo, kad didesn\u012f u\u017e normal\u0173 (KMI &gt; 25) turi daugiau kaip 65 proc. Austrijos, \u010cekijos, Vokietijos, Anglijos, \u0160kotijos, Airijos vyr\u0173 ir daugiau negu 50 proc. Austrijos, Bulgarijos, \u010cekijos, Anglijos, Vokietijos, \u0160kotijos moter\u0173. Europoje liekniausi Pranc\u016bzijos, Olandijos, \u0160vedijos gyventojai. Antsvoris (KMI \u2013 25 daugiau) ir <a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/nutukimas\/4355\">nutukimas<\/a> (KMI \u2013 30 arba daugiau) n\u0117ra tik estetin\u0117 problema.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Per didelis k\u016bno svoris skatina \u012fvairi\u0173 organ\u0173 ir organizmo sistem\u0173 pa\u017eeidimus, kurie gali sukelti sunki\u0173 sveikatos sutrikim\u0173, ne\u012fgalum\u0105 ir prie\u0161laikin\u0119 mirt\u012f. Da\u017eniausios nutukimo komplikacijos:<\/span><\/p>\n<ul style=\"margin-top: 0cm;\">\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l2 level1 lfo1; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">plau\u010di\u0173 ligos (<a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/miego-apneja\/4422\">miego apn\u0117ja<\/a>, hiperventiliacijos sindromas, kv\u0117pavimo disfunkcija);<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l2 level1 lfo1; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">nealkoholinis riebalinis kepen\u0173 pa\u017eeidimas (steatoz\u0117, steatohepatitas, ciroz\u0117, hepatoma);<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l2 level1 lfo1; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">tul\u017eies p\u016bsl\u0117s ligos (diskinezijos, akmenlig\u0117);<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l2 level1 lfo1; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">\u0160KL (arterin\u0117 hipertenzija, <a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/isemine-sirdies-liga\/4518\">i\u0161emin\u0117 \u0161irdies liga<\/a>);<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l2 level1 lfo1; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">CD, atsparumas insulinui, dislipidemija;<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l2 level1 lfo1; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">katarakta;<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l2 level1 lfo1; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">ginekologin\u0117s ligos (<a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/menesiniu-ciklo-sutrikimai\/4305\">m\u0117nesini\u0173 ciklo sutrikimai<\/a>, <a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/policistiniu-kiausidziu-sindromas\/55684\">policistini\u0173 kiau\u0161id\u017ei\u0173 sindromas<\/a>, nevaisingumas);<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l2 level1 lfo1; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">pankreatitas;<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l2 level1 lfo1; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">piktybiniai navikai (gimdos, stor\u0173j\u0173 \u017earn\u0173, prostatos, stempl\u0117s, kasos, inkst\u0173 ir kt.);<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l2 level1 lfo1; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\"><a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/artroze\/4306\">osteoartritas<\/a>;<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l2 level1 lfo1; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">podagra;<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l2 level1 lfo1; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">ven\u0173 ligos (flebitas ir kt.);<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l2 level1 lfo1; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">odos ligos.<\/span><\/li>\n<\/ul>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><b><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 13.0pt;\">\u00a0<\/span><\/b><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><b><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 13.0pt;\">Atsparumas insulinui \u2013 centrinis mechanizmas<\/span><\/b><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">\u00a0<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Nutukimo sukelt\u0173 organizmo pa\u017eeidim\u0173 grandin\u0117je viena svarbiausi\u0173 grand\u017ei\u0173 yra atsparumo<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">insulinui sindromas. Jo atsiradim\u0105 lemia daug genetini\u0173, gyvensenos, elgsenos ir psichogenini\u0173 veiksni\u0173. Atsparumo insulinui sindromas, kuris neretai lydi nutukim\u0105 (ypa\u010d<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">juosmenin\u012f) b\u016bdingas padid\u0117j\u0119s insulino kiekis kraujyje, dislipidemija (ir hipertrigliceridemija), koaguliacijos sutrikimai, aterotromboz\u0117, padid\u0117j\u0119s u\u017edegimo \u017eymen\u0173 kiekis).<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Eksperimenti\u0161kai ir klinikiniais tyrimais \u012frodyta, kad <a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/nutukimas\/4355\">nutukimas<\/a> ir su juo susij\u0119s atsparumas insulinui turi tiesiogin\u012f ry\u0161\u012f su ateroskleroze, aterotromboze ir kitais pavojingais kraujagysli\u0173 pa\u017eeidimais. Pavojingiausias yra juosmeninis <a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/nutukimas\/4355\">nutukimas<\/a>, kuris aktyviai skatina:<\/span><\/p>\n<ul style=\"margin-top: 0cm;\">\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l4 level1 lfo2; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">atsparum\u0105 insulinui;<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l4 level1 lfo2; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">endotelio disfunkcij\u0105 (suma\u017e\u0117ja NO sintez\u0117 ir i\u0161skyrimas);<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-list: l4 level1 lfo2; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">hiperglikemij\u0105 ir dislipidemij\u0105;<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l4 level1 lfo2; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">arterin\u0119 hipertenzij\u0105;<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l4 level1 lfo2; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">u\u017edegimo reakcijas;<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l4 level1 lfo2; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">hiperkoaguliacij\u0105;<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l4 level1 lfo2; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">aterogenez\u0119.<\/span><\/li>\n<\/ul>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">\u0160ie metaboliniai ir homeostaz\u0117s veiksniai, veikdami sinergi\u0161kai, aktyviai skatina ateroskleroz\u0117s progresavim\u0105 ir didina \u0160KL komplikacij\u0173 rizik\u0105.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><b><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 13.0pt;\">\u00a0<\/span><\/b><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><b><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 13.0pt;\">Pavojingas tercetas<\/span><\/b><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">\u00a0<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Itin pavojingas \u0161irdies ir kraujagysli\u0173 sistemai ateroskleroz\u0117s, arterin\u0117s hipertenzijos ir CD derinys. Sergantieji arterine hipertenzija ir CD \u201eautomati\u0161kai\u201c priskiriami labai didel\u0117s \u0160KL rizikos grupei:<\/span><\/p>\n<ul style=\"margin-top: 0cm;\">\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l6 level1 lfo3; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">65 proc. mir\u010di\u0173 sergant CD lemia \u0160KL;<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l6 level1 lfo3; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">sergant \u0160KL ir CD prognoz\u0117 yra reik\u0161mingai blogesn\u0117 nei sergant \u0160KL be CD;<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l6 level1 lfo3; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">da\u017eniausios CD komplikacijos: <a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/isemine-sirdies-liga\/4518\">i\u0161emin\u0117 \u0161irdies liga<\/a>, insultas, periferini\u0173 kraujagysli\u0173 liga, nefropatija, retinopatija, neuropatija ir \u0161irdies nepakankamumas;<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l6 level1 lfo3; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">miego arterijos (<i>a. carotis<\/i>) <a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/ateroskleroze\/4332\">ateroskleroz\u0117<\/a> ir negr\u012f\u017etami smegen\u0173 parenchimos poky\u010diai po insulto da\u017enesni asmenims, sergantiems CD.<\/span><\/li>\n<\/ul>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">\u0160irdies ir kraujagysli\u0173 sistemos bei kit\u0173 organ\u0173 taikini\u0173 pa\u017eeidim\u0173 profilaktikai sergant CD svarbiausia yra gera metabolin\u0117 CD kontrol\u0117: tikslini\u0173 glikemijos, lipid\u0173 pusiausvyros bei kit\u0173 parametr\u0173 palaikymas. To pasiekiama gydant geriamaisiais antidiabetiniais vaistais ir insulinu.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\"><\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><b><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 13.0pt;\">Metforminas: \u012fvairiapusis metabolinis poveikis<\/span><\/b><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">\u00a0<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Naujausi moksliniai tyrimai rodo, kad biguanid\u0173 klas\u0117s preparatas metforminas vienintelis pasi\u017eymi reik\u0161mingu kardioprotekciniu veikimu, nepriklausomu nuo glikemijos kontrol\u0117s. Pleotropinio organus apsaugan\u010dio metformino poveikio mechanizmas sud\u0117tingas ir daugialypis:<\/span><\/p>\n<ul style=\"margin-top: 0cm;\">\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l3 level1 lfo6; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">gerina kraujagysli\u0173 endotelio funkcij\u0105, skatina NO sintez\u0119, i\u0161siskyrim\u0105 ir sistemin\u0119 vazodiliatacij\u0105;<\/span><\/li>\n<\/ul>\n<ul style=\"margin-top: 0cm;\">\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l1 level1 lfo4; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">gerina kraujagysli\u0173 atsak\u0105 \u012f vazodilatacini\u0173 med\u017eiag\u0173 poveik\u012f;<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l1 level1 lfo4; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">ma\u017eina kraujo kre\u0161\u0117jim\u0105 skatinan\u010di\u0173 faktori\u0173 kiek\u012f ir aktyvum\u0105, gerina reologines kraujo savybes ir mikrocirkuliacij\u0105;<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l1 level1 lfo4; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">suma\u017eina plazmos aterogenin\u012f aktyvum\u0105;<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l1 level1 lfo4; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">padidina adiponektino kiek\u012f ir l\u0105steli\u0173 jautrum\u0105 insulinui.<\/span><\/li>\n<\/ul>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Iki \u0161iol did\u017eiausias ir ilgiausios trukm\u0117s (per de\u0161imt met\u0173) klinikinis epidemiologinis CD tyrimas UKPDS \u012frod\u0117 patikim\u0105 ir klini\u0161kai reik\u0161ming\u0105 metformino prana\u0161um\u0105, palyginti su sulfanilkarbamidais (sulfanil\u0161lapalo preparatais), gydant nutukusius CD sergan\u010dius pacientus.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Metforminas reik\u0161mingai labiau negu sulfanil\u0161lapalo (SUL) preparatai suma\u017eino vis\u0173 svarbiausi\u0173 CD baig\u010di\u0173 ir \u0160KL komplikacij\u0173 da\u017enum\u0105.<\/span><\/p>\n<ul style=\"margin-top: 0cm;\">\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l0 level1 lfo5; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Vis\u0173 su CD susijusi\u0173 baig\u010di\u0173 da\u017enumas gydant metforminu suma\u017e\u0117jo 32 proc., gydant SUL \u2013 7 proc.<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l0 level1 lfo5; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Mir\u010di\u0173, susijusi\u0173 su CD, gydant metforminu suma\u017e\u0117jo 42 proc., gydant SUL \u2013 20 proc.<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l0 level1 lfo5; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Miokardo infarkto da\u017enumas gydant metforminu suma\u017e\u0117jo 39 proc., gydant SUL \u2013 21 proc.<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l0 level1 lfo5; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Insulto da\u017enumas gydant metforminu suma\u017e\u0117jo 41 proc., gydant SUL \u2013 netgi padid\u0117jo 14 proc.<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l0 level1 lfo5; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Smulki\u0173j\u0173 kraujagysli\u0173 pa\u017eeidim\u0173 (komplikacij\u0173) da\u017enumas gydant metforminu suma\u017e\u0117jo 29 proc., gydant SUL \u2013 16 proc.<\/span><\/li>\n<\/ul>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Metformino l\u0105stelinio veikimo mechanizmas sud\u0117tingas ir iki galo nei\u0161siai\u0161kintas. Nustatyta, kad metforminas aktyvina l\u0105steli\u0173 plazmin\u0117s membranos potencial\u0105, padidina insulinui specifi\u0161k\u0173 receptori\u0173 jautrum\u0105, reguliuoja gliukoz\u0117s ir lipid\u0173 apykaitoje dalyvaujan\u010di\u0173 ferment\u0173 aktyvum\u0105, gerina mitochondrij\u0173 funkcij\u0105 ir l\u0105steli\u0173 energinius procesus, netgi pasi\u017eymi CD raidai svarbiais genominiais efektais, slopina \u017ealingas oksidacinio streso reakcijas, padeda reguliuoti lipid\u0173 pusiausvyr\u0105.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Pastaraisiais metais metforminas prad\u0117tas efektyviai taikyti \u012fvairi\u0173 su nutukimu ir atsparumu insulinui susijusi\u0173 lig\u0173 gydymui bei profilaktikai. Metformino veiksmingumas esant \u0161ioms patologin\u0117ms b\u016bkl\u0117ms \u012frodytas moksliniais klinikiniais tyrimais.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><b><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 13.0pt;\">\u00a0<\/span><\/b><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><b><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 13.0pt;\"><a href=\"https:\/\/pasveik.lt\/ligos-ir-sindromai\/nutukimas\/4355\">Nutukimas<\/a> ir kepen\u0173 ligos<\/span><\/b><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">\u00a0<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Pasaulyje labiausiai paplitusios kepen\u0173 ligos yra C ir B hepatito virusin\u0117 infekcija (A hepatitu dabartiniais laikais sergama daug re\u010diau, bet Piet\u0173 Amerikoje vis dar gana da\u017enai), alkoholinis <a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/hepatitas\/4350\">hepatitas<\/a> ir <a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/kepenu-ciroze\/4356\">kepen\u0173 ciroz\u0117<\/a>, nealko holin\u0117 steatohepatoz\u0117 (kepen\u0173 surieb\u0117jimas) ir nealkoholinis steatohepatitas bei j\u0173 komplikacijos.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Stiprios ekonomikos \u0161alyse nealkoholini\u0173 ir neinfekcini\u0173 kepen\u0173 pa\u017eeidim\u0173 paplitimas<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">did\u0117ja. \u0160ie pa\u017eeidimai patogenezi\u0161kai susij\u0119 su nutukimu ir atsparumu insulinui. Autopsij\u0173 duomenimis, 20\u201330 proc. suaugusi\u0173 stiprios ekonomikos \u0161ali\u0173 gyventoj\u0173 pasirei\u0161kia nealkoholinio kepen\u0173 surieb\u0117jimo po\u017eymi\u0173, i\u0161 j\u0173 2\u20133 proc. diagnozuojamas nealkoholinis steatohepatitas.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Nealkoholinis kepen\u0173 surieb\u0117jimas nustatomas 65\u201375 proc. \u017emoni\u0173, kuri\u0173 KMI &gt; 30, ir apie 90 proc. \u017emoni\u0173, kuri\u0173 KMI &gt; 35. I\u0161 asmen\u0173, turin\u010di\u0173 nealkoholin\u012f kepen\u0173 surieb\u0117jim\u0105, 45\u201390 proc. yra nutuk\u0119, daugiau kaip 50 proc. serga 2 tipo CD, daugiau kaip 80 proc. asmen\u0173 sutrikusi lipid\u0173 apykaita.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Nealkoholinio kepen\u0173 surieb\u0117jimo patofiziologija sud\u0117tinga. Steatohepatoz\u0117s formavim\u0105si lemia u\u017esit\u0119susi nekoreguojama dislipidemija, suaktyv\u0117j\u0119s riebal\u0173 kaupimasis kepenyse, intrahepatinis oksidacinis stresas, peroksidin\u0117 lipid\u0173 oksidacija, autoimuniniai u\u017edegimo veiksniai (ypa\u010d imunini\u0173 l\u0105steli\u0173 gaminami citokinai, i\u0161 j\u0173 ir TNF-alfa).<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Nealkoholinis kepen\u0173 surieb\u0117jimas yra potencialiai pavojinga b\u016bkl\u0117, nes negydoma gali pereiti \u012f nealkoholin\u012f steatohepatit\u0105, o \u0161is \u2013 \u012f kepen\u0173 fibroz\u0119, ciroz\u0119 ar netgi pirmin\u012f kepen\u0173 v\u0117\u017e\u012f. Nealkoholinio kepen\u0173 surieb\u0117jimo per\u0117jim\u0105 \u012f steatohepatit\u0105 atspindi pasikeit\u0119s strukt\u016brinis<\/span> <span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">kepen\u0173 vaizdas, nustatomas tiriant ultragarsu, kompiuterine, magnetinio rezonanso tomografija) ir atsirad\u0119 aktyvaus u\u017edegimo po\u017eymiai: truput\u012f padid\u0117j\u0119s ALT ir AST aktyvumas, didesnis nei 1 ALT ir AST santykis, kepen\u0173 bioptato poky\u010diai.<\/span> <span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Nealkoholinio kepen\u0173 surieb\u0117jimo gydymas turi b\u016bti kompleksinis, ilgas: taikoma dieta, nemedikamentinio poveikio priemon\u0117s ir skiriama vaist\u0173.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Labai svarbu normalizuoti paciento k\u016bno mas\u0119 ir lipid\u0173 pusiausvyr\u0105. Jei pacientas serga CD, b\u016btina grie\u017eta glikemijos ir kit\u0173 metabolizmo parametr\u0173 kontrol\u0117. Pacientas privalo labai riboti (iki abstinencijos) alkoholio vartojim\u0105, nevartoti hepatotoksini\u0173 med\u017eiag\u0173 ir vaist\u0173.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Fizinis aktyvumas turi b\u016bti pakankamas, bet negalima pervargti. Jei \u0161iomis priemon\u0117mis nepavyksta efektyviai suma\u017einti k\u016bno svorio, taikomas medikamentinis ar net chirurginis nutukimo gydymas.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Nealkoholinio kepen\u0173 surieb\u0117jimo gydymui ir profilaktikai svarbu ma\u017einti atsparum\u0105 insulinui. Naujausi klinikiniai tyrimai rodo, kad labai ger\u0173 rezultat\u0173 pasiekiama gydant metforminu. Mokslini\u0173 tyrim\u0173 duomenimis, sergan\u010diuosius steatohepatoze ir steatohepatitu gydant<\/span> <span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">metforminu, suma\u017einus atsparum\u0105 insulinui, reik\u0161mingai pager\u0117jo kepen\u0173 strukt\u016bra ir funkcijos, susilpn\u0117jo u\u017edegimo aktyvumas kepen\u0173 parenchimoje, t. y. reik\u0161mingai suma\u017e\u0117jo ar netgi normalizavosi ALT aktyvumas, pager\u0117jo ultragarsinis kepen\u0173 vaizdas (normalizavosi kepen\u0173 strukt\u016bra).<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><b><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 13.0pt;\">\u00a0<\/span><\/b><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><b><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 13.0pt;\"><a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/policistiniu-kiausidziu-sindromas\/55684\">Policistini\u0173 kiau\u0161id\u017ei\u0173 sindromas<\/a><\/span><\/b><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">\u00a0<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Sukaupta nema\u017eai duomen\u0173, \u012frodan\u010di\u0173, kad hiperinsulinemija ir atsparumas insulinui bei <a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/nutukimas\/4355\">nutukimas<\/a> (ypa\u010d juosmeninis) atlieka svarbiausi\u0105 vaidmen\u012f policistini\u0173 kiau\u0161id\u017ei\u0173 sindromo (PKS) patogenez\u0117je. Esama duomen\u0173, kad hiperinsulinemija skatina steroidogenez\u0119 kiau\u0161id\u0117se: moters organizme daug\u0117ja androgen\u0173, susilpn\u0117ja sintez\u0117 lytinius hormonus sujungian\u010dio faktoriaus ir baltymo, sujungian\u010dio \u012f insulin\u0105 pana\u0161\u0173 augimo faktori\u0173, tod\u0117l kiau\u0161id\u0117s gaminasi ma\u017eiau moteri\u0161k\u0173j\u0173 lytini\u0173 hormon\u0173. \u0160ie hormon\u0173 pusiausvyros poky\u010diai<\/span>\u00a0 <span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">b\u016bdingi PKS.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">PKS daugeliu atvej\u0173 b\u016bna susij\u0119s su metaboliniais sutrikimais ar j\u0173 lydimas. Kai kuri\u0173 tyrim\u0173 duomenimis, iki 50 proc. PKS sergan\u010di\u0173 moter\u0173 nustatomas metabolinis sindromas: dislipidemija, atsparumas insulinui, gliukoz\u0117s toleravimo sutrikimas arba CD ir kt.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Esant policistini\u0173 kiau\u0161id\u017ei\u0173 sindromui, b\u016bdinga hormon\u0173, metaboliniai poky\u010diai, kiau\u0161id\u017ei\u0173 disfunkcija bei strukt\u016bros pakitimai. Da\u017eniausiai funkcijos sutrikimai pasirei\u0161kia oligomenor\u0117ja ar disfunkciniu kraujavimu, anovuliaciniu nevaisingumu, hirsutizmu ir akne, juosmeniniu nutukimu.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Sutrikusi\u0105 hormon\u0173 pusiausvyr\u0105 rodo padid\u0117j\u0119s testosterono kiekis, padid\u0117j\u0119s liuteininio hormono kiekis esant normaliam folikulus stimuliuojan\u010dio hormono kiekiui, atsparumu insulinui, kur\u012f lydi kompensacin\u0117 hiperinsulinemija. Tiriant ultragarsu matyti pakitusi kiau\u0161id\u017ei\u0173<\/span> <span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">strukt\u016bra: kiau\u0161id\u017ei\u0173 stromos echotankis padid\u0117j\u0119s, periferijoje gausu ma\u017e\u0173 folikul\u0173. PKS gydomas kompleksi\u0161kai: normalizuojamas sutrik\u0119s m\u0117nesini\u0173 ciklas, koreguojama hiperandrogenemija (<a href=\"https:\/\/pasveik.lt\/lt\/ligos-ir-sindromai\/hirsutizmas\/72642\">hirsutizmas<\/a>, akn\u0117), gydomas anovuliacinis nevaisingumas. Efektyviai gydyti PKS ne\u012fmanoma nekoregavus metabolini\u0173 sutrikim\u0173, kurie patogenezi\u0161kai yra centriniai, lemiantys ar predisponuojantys hormon\u0173<\/span> <span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">ir kitus sutrikimus.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Pastaraisiais metais labai ger\u0173 rezultat\u0173 pasiekta PKS gydant metforminu. Metformino veiksmingum\u0105 galima paai\u0161kinti tuo, kad \u0161is vaistas efektyviai veikia svarbiausias metabolines patofiziologines PKS grandis ir parametrus: atsparum\u0105 insulinui, hiperinsulinemij\u0105, nutukim\u0105, dislipidemij\u0105, hiperglikemij\u0105, hiperandrogenizm\u0105, anovuliacin\u012f nevaisingum\u0105.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Klinikiniai tyrimai rodo, kad PKS gydant metforminu:<\/span><\/p>\n<ul style=\"margin-top: 0cm;\">\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l5 level1 lfo7; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">skatinama ovuliacija;<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l5 level1 lfo7; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">apsaugoma nuo n\u0117\u0161tumo nutr\u016bkimo pirm\u0105j\u012f trimestr\u0105;<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l5 level1 lfo7; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">suma\u017e\u0117ja n\u0117\u0161\u010di\u0173j\u0173 diabeto ir vaisiaus makrosomijos atvej\u0173.<\/span><\/li>\n<li class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none; mso-list: l5 level1 lfo7; tab-stops: list 36.0pt;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">n\u0117ra klini\u0161kai reik\u0161mingo teratogeninio poveikio, nesutrinka fiziologinis vaisiaus augimas ir raida.<\/span><\/li>\n<\/ul>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Vidutin\u0117 optimali terapin\u0117 metformino doz\u0117 gydant PKS yra 500 mg 3 kartus per dien\u0105, o gydant CD \u2013 1000 mg 2 kartus per dien\u0105.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><b><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 13.0pt;\">\u00a0<\/span><\/b><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><b><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 13.0pt;\">Metforminas ir CD profilaktika<\/span><\/b><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">\u00a0<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">Daugeliu labai patikim\u0173 klinikini\u0173 tyrim\u0173 \u012frodyta, kad metforminas veiksmingas ir saugus gydant 2 tipo CD, apsaugant nuo diabetini\u0173 kraujagyslini\u0173 ir neurogenini\u0173 komplikacij\u0173, organ\u0173 taikini\u0173 pa\u017eeidim\u0173 ir gyvybei gr\u0117smingas komplikacij\u0173. Pastaraisiais metais atliktos mokslin\u0117s studijos duoda pagrindo teigti, kad metforminas labai efektyvus ir CD profilaktikai. <i>N. England J. Med. <\/i>\u017eurnale paskelbtose Diabeto profilaktikos programos tyrim\u0173 grup\u0117s i\u0161vadose nurodoma, kad metforminas gali iki 31 proc. suma\u017einti CD da\u017enum\u0105, palyginti su placebu, kai \u0161ios ligos rizika yra padid\u0117jusi. Jei vartojant metformin\u0105 kartu pakei\u010diama gyvensena ir pasitelkiami kiti metaboli\u0161kai palank\u016bs veiksniai, CD rizika suma\u017e\u0117ja itin reik\u0161mingai. Kai kuriose stiprios ekonomikos \u0161alyse jau u\u017eregistruota indikacija skirti metformino cukrinio diabeto profilaktikai.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 9.0pt;\">\u00a0<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify;\"><i><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 11.0pt;\">Pareng\u0117 <b>gyd. J. Kastys<\/b><\/span><\/i><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify;\"><b><i><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 11.0pt;\">\u00a0<\/span><\/i><\/b><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify;\"><b><i><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 11.0pt;\">Lietuvos gydytojo \u017eurnalas<\/span><\/i><\/b><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 12.0pt;\"><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 0pt; text-align: justify; mso-layout-grid-align: none;\"><span style=\"font-size: 10pt; font-family: Arial; mso-ansi-language: LT; mso-bidi-font-size: 11.0pt;\">\u0160irdies ir kraujagysli\u0173 ligos daugumoje pasaulio \u0161ali\u0173 teb\u0117ra svarbiausia gyventoj\u0173 sergamumo ir mirtingumo prie\u017eastis. J\u0173 atsiradim\u0105 ir progresavim\u0105 skatina <a href=\"https:\/\/pasveik.lt\/ligos-ir-sindromai\/arterine-hipertenzija\/4333\">arterin\u0117 hipertenzija<\/a>, sutrikusi lipid\u0173 pusiausvyra, u\u017edegimo ir kitokie, dar ne visi\u0161kai identifikuoti kraujagysles pa\u017eeid\u017eiantys veiksniai. Pastaraisiais metais atlikti moksliniai tyrimai rodo, kad \u0161irdies ir kraujagysli\u0173 lig\u0173 (\u0160KL) rizikos strukt\u016broje reik\u0161mingas vaidmuo tenka \u0161iems veiksniams: cukriniam diabetui (CD), atsparumui insulinui ir kitiems metabolizmo sutrikimams, taip pat antsvoriui ir nutukimui. \u012esid\u0117m\u0117tina, kad visos \u0161ios patologin\u0117s b\u016bkl\u0117s, ne tik skatina formuotis \u0161irdies ir kraujagysli\u0173 pa\u017eeidimus, bet ir yra tarpusavyje susijusios patofiziologiniais ry\u0161iais.<\/span><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[27313],"tags":[7488,39,1012,1537,431,141,1036,157,5972,259,415,24,21,8106,138],"site":[],"post_item_type":[27345],"class_list":["post-11238","post","type-post","status-publish","format-standard","hentry","category-gydymo-naujienos","tag-ciroze","tag-dieta","tag-disfunkcija","tag-hiperinsulinemija","tag-hipertenzija","tag-insultas","tag-metforminas","tag-nutukimas","tag-pacientas","tag-preparatai","tag-profilaktika","tag-profilaktikai","tag-sindromas","tag-sinteze","tag-vaistai"],"acf":{"post_sites":false},"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/posts\/11238","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/comments?post=11238"}],"version-history":[{"count":0,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/posts\/11238\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/media?parent=11238"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/categories?post=11238"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/tags?post=11238"},{"taxonomy":"site","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/site?post=11238"},{"taxonomy":"post_item_type","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/post_item_type?post=11238"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}